Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Monica Minarelli"'
Autor:
Elisabetta Tonet, Andrea Rubboli, Monica Minarelli, Davide Bernucci, Francesco Vitali, Simone Biscaglia, Marcello Galvani, Matteo Serenelli, Rossella Ruggiero, Rita Pavasini, Paolo Cimaglia, Gianluca Campo, Matteo Tebaldi, Elisa Maietti, Stefano Volpato, Giulia Bugani
Publikováno v:
Cardiovascular Drugs and Therapy. 33:523-532
Hitherto, no study has yielded important information on whether the scales of frailty may improve the ability to discriminate the risk of haemorrhages in older adults admitted to hospital for acute coronary syndrome (ACS). The aim of this study is to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57ea58e6eacc3f144fe42a36a28f1953
https://doi.org/10.1007/s10557-019-06911-y
https://doi.org/10.1007/s10557-019-06911-y
Autor:
Juan Sanchis, Roberto Ferrari, Monica Minarelli, Gianluca Campo, Marcello Galvani, Elisabetta Tonet, Francesco Vitali, Stefano Volpato, Rossella Ruggiero, Albert Ariza-Solé, Simone Biscaglia, Rita Pavasini, Jack M. Guralnik, Francesc Formiga, Paolo Cimaglia, Giulia Ricci Lucchi, Giulia Bugani, Matteo Serenelli, Matteo Tebaldi, Elisa Maietti
Background The number of older adults admitted to hospital for acute coronary syndrome (ACS) has increased worldwide. The aim of this study was to determine which scale of frailty or physical performance provides incremental improvements in risk stra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a21450d0d2bd84b72f1dafa3635d473
http://hdl.handle.net/11392/2406760
http://hdl.handle.net/11392/2406760
Autor:
Pascal Vranckx, Caterina Cavazza, Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Monica Minarelli, Jlenia Marchesini, Carlo Tumscitz, Marco Borghesi, Elisa Cangiano, Giovanni Parrinello, Antonella Scalone, Prodigy Investigators
Publikováno v:
JACC-Cardiovascular interventions, 7(1), 20-28. Elsevier Inc.
Objectives This study sought to assess device-specific outcomes after implantation of bare-metal stents (BMS), zotarolimus-eluting Endeavor Sprint stents (ZES-S), paclitaxel-eluting stents (PES), or everolimus-eluting stents (EES) (Medtronic Cardiova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd8c7101f1ff07468c5588bc95d0e366
https://hdl.handle.net/1765/69313
https://hdl.handle.net/1765/69313
Autor:
Michele Malagù, Giovanni Pasanisi, Matteo Bertini, Giuseppe Fucà, Biagio Sassone, Luigi Padeletti, Helene Afi Kuwornu, Monica Minarelli, Nicola Avigni, Matteo Beltrami, Maria Letizia Bacchi Reggiani, Federico Pacchioni
Publikováno v:
The American journal of cardiology. 119(11)
Left ventricular (LV) dyssynchrony (LVdys) is a necessary condition for successful cardiac resynchronization therapy (CRT). Despite left bundle branch block (LBBB) representing a reliable surrogate of LVdys, not all LBBB patients will respond to CRT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f21c30613cc516a464adf9e8d9d0329
https://pubmed.ncbi.nlm.nih.gov/28391991
https://pubmed.ncbi.nlm.nih.gov/28391991
Autor:
Monica Minarelli, Marco Valgimigli
Publikováno v:
American Heart Journal. 160:S36-S41
Antiplatelet therapy has been shown to significantly reduce the risk of serious vascular events in high-risk patients, including those with a prior acute ischemic event. The long-term use of antiplatelet agents is a key component of secondary prevent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3299bc86bac365b138d4a57540909ea7
https://doi.org/10.1016/j.ahj.2010.10.014
https://doi.org/10.1016/j.ahj.2010.10.014
Autor:
Roberto Ferrari, Marco Borghesi, Antonella Scalone, Fabrizio Ferrari, Caterina Cavazza, Jlenia Marchesini, Marco Valgimigli, Andrea Zuffi, Giovanni Parrinello, Carlo Tumscitz, Chiara Arcozzi, Monia Monti, Gianluca Campo, Gianfranco Percoco, Alice Frangione, Elisa Cangiano, Monica Minarelli, Federico Colombo, Matteo Tebaldi, Moh'd Kubbajeh
Publikováno v:
American Heart Journal. 160:804-811
Background The optimal duration of clopidogrel therapy after coronary stenting is debated because of the scarcity of randomized controlled trials and inconsistencies arising from registry data. Although prolonged clopidogrel therapy after bare metal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::561fe102105b4b6fd3140178d52dc37a
https://doi.org/10.1016/j.ahj.2010.07.034
https://doi.org/10.1016/j.ahj.2010.07.034
Autor:
Marco, Valgimigli, Matteo, Tebaldi, Marco, Borghesi, Pascal, Vranckx, Gianluca, Campo, Carlo, Tumscitz, Elisa, Cangiano, Monica, Minarelli, Antonella, Scalone, Caterina, Cavazza, Jlenia, Marchesini, Giovanni, Parrinello, G, Fuca
Publikováno v:
JACC. Cardiovascular interventions. 7(1)
This study sought to assess device-specific outcomes after implantation of bare-metal stents (BMS), zotarolimus-eluting Endeavor Sprint stents (ZES-S), paclitaxel-eluting stents (PES), or everolimus-eluting stents (EES) (Medtronic Cardiovascular, San
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a42eb9e8d9a7caa01dea764d2e7b5313
https://pubmed.ncbi.nlm.nih.gov/24332420
https://pubmed.ncbi.nlm.nih.gov/24332420
Autor:
Pascal Vranckx, Jlenia Marchesini, Fausto Castriota, Giovanni Parrinello, Marco Valgimigli, Roberto Ferrari, Federico Colombo, Antonella Scalone, Elisa Cangiano, Matteo Tebaldi, Carlo Tumscitz, Giuseppe Fucà, Marco Borghesi, Caterina Cavazza, Alice Frangione, Gianfranco Percoco, Monia Monti, Gianluca Campo, Monica Minarelli, Moh'd Kubbajeh
Background— The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e329e5adb81879c8fb28c9bbcf0366f7
http://hdl.handle.net/11392/1690383
http://hdl.handle.net/11392/1690383
Autor:
Marco Valgimigli, Monica Minarelli
Publikováno v:
Drugs. 71(13)
Heightened platelet activity plays a critical role in thrombus formation, which is central to acute coronary syndromes (ACS), including non-ST-segment elevation (NSTE)-ACS (comprising unstable angina pectoris and non-ST-segment elevation myocardial i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c33d80a97a3d58406e7fce6ed591ab
https://pubmed.ncbi.nlm.nih.gov/21902293
https://pubmed.ncbi.nlm.nih.gov/21902293
Autor:
Marco, Valgimigli, Gianluca, Campo, Gianfranco, Percoco, Monia, Monti, Fabrizio, Ferrari, Carlo, Tumscitz, Andrea, Zuffi, Federico, Colombo, Moh'd, Kubbajeh, Caterina, Cavazza, Elisa, Cangiano, Matteo, Tebaldi, Monica, Minarelli, Chiara, Arcozzi, Antonella, Scalone, Alice, Frangione, Marco, Borghesi, Jlenia, Marchesini, Giovanni, Parrinello, Roberto, Ferrari
Publikováno v:
American heart journal. 160(5)
The optimal duration of clopidogrel therapy after coronary stenting is debated because of the scarcity of randomized controlled trials and inconsistencies arising from registry data. Although prolonged clopidogrel therapy after bare metal stenting is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d00617b8c2cdf902e5abd4f61e067b55
https://pubmed.ncbi.nlm.nih.gov/21095265
https://pubmed.ncbi.nlm.nih.gov/21095265